Speech-Language Pathologists in Evanston, WY Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Stacy Barker Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 350 City View Drive, Evanston, WY 82930 Phone: 307-789-7384 |
Tyrell Janiga Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 350 City View Drive, Evanston, WY 82930 Phone: 307-789-7384 |
Ms. Nena M. Germany-greer, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 417 Lucas Ave, Evanston, WY 82930 Phone: 307-789-0815 |
Katrina Hurst, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 130 Colonial Ave, Evanston, WY 82930 Phone: 801-712-0145 |
News Archive
Health plans launch initiative to make delivering and getting health care easier for patients and their physicians
Health plans today launched a landmark initiative to make delivering and getting health care easier for patients and their physicians by reducing the time, effort, and expense for the "paperwork" required for each patient office visit. The initiative, which will simplify information flow between health plans and doctors' offices, and later between health plans and hospitals, is comparable to what ATMs did for banks and consumers.
Signostics raises $5M in oversubscribed round of financing from new and existing investors
Signostics Inc., a U.S. and Australian-based medical device company developing revolutionary and affordable palm-sized ultrasound devices, has raised $5 million in an oversubscribed round of financing from new and existing investors. The company has raised a total of $19 million to date.
Legacy Biotechnologies, Phillips Sales and Marketing reach agreement to distribute Reme-Flu remedy
Nuvilex, Inc., announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™ homeopathic flu remedy, has reached an agreement with Phillips Sales and Marketing to begin the national sales and marketing campaign for retail distribution of Reme-Flu™.
High ADAR1 enzyme levels correlate with reduced survival rates in multiple myeloma
Multiple myeloma is the second most common blood cancer in the United States. Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1.
› Verified 9 days ago
Physical Therapists
Optometrists
Chiropractors
Speech-Language Pathologists
Occupational Therapists
Podiatrists